News

From cell biology to CRISPR gene editing technology – the Life Science Learning Lab at the Berlin-Buch research campus offers both students and teachers the opportunity to immerse themselves in science. This year, “Gläsernes Labor” celebrates its 25th anniversary.

He is a molecular biologist and physician, a GDR civil rights activist and bioethicist, a person with integrity and a sense of community. Until 2022, he was an ombudsman at the Max Delbrück Center. We celebrate the 85th birthday of Professor Jens Reich.

The German Research Foundation (DFG) will fund single-cell scientist Simon Haas in its Heisenberg program. Therefore, the Berlin Institute of Health at Charité (BIH) is establishing a Heisenberg professorship in systems hematology. After five years, the BIH will make the professorship permanent.

NOVA University and Max Delbrück Center are jointly establishing the NOVA Institute for Medical Systems Biology (NIMSB). Both institutions have developed a shared vision to push the boundaries of precision medicine. “Insights” spoke to the three project leads in Lisbon and Berlin.

This year, young researchers from Berlin were once again drawn to the regional competition "Jugend forscht". Pictures and videos provide insight into the colorful competition on the Berlin-Buch Campus.

During three campaigns in December 2023, employees of the Max Delbrück Center took the opportunity to donate to good causes. This resulted in more than 300 gifts for children and more than 1,400 euros for the 'Kältebus' (cold bus) for homeless people in Berlin. We spoke with the organizers.

The artists Elisabetta Citterio and Claudia Cagliano have created portraits of nearly 60 female researchers from nine countries. Twenty-five of them can be viewed in the "STEM Passion" exhibition until March 12, 2024 in the Rahel Hirsch Center for Translational Medicine Berlin.

A new computer program allows scientists to design synthetic DNA segments that indicate, in real time, the state of cells. Reported by the Gargiulo lab in “Nature Communications”, it will be used to screen for anti-cancer or viral infections drugs, or to improve gene and cell-based immunotherapies.

Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in “Science Immunology.”